Literature DB >> 12822876

Effect of Lactobacillus-fermented diets on bacterial translocation and intestinal flora in experimental prehepatic portal hypertension.

R Wiest1, F Chen, G Cadelina, R J Groszmann, G Garcia-Tsao.   

Abstract

Spontaneous bacterial infections in cirrhosis and portal hypertension have been attributed to translocation of gut-derived bacteria, a process promoted by intestinal bacterial overgrowth and disruption of the gut mucosal barrier. Bacteriotherapy with Lactobacillus has been reported to correct bacterial overgrowth, stabilize mucosal barrier function, and decrease bacterial translocation in rat models of acute liver injury and failure. In this study we investigated the effect of Lactobacillus-supplemented diets on intestinal flora and on bacterial translocation rate in portal vein ligated rats. Lactobacillus-fermented milk (yogurt) containing at least 2 x 10(9) colony forming units/ml or placebo (water) was adminstrated by gavage twice daily (2 ml) for 9 days. Portal vein ligation was performed on day 7 of treatment. Bacterial translocation to mesenteric lymph nodes and quantification of intestinal flora was assessed by standard bacteriological cultures. Bacterial translocation was not significantly different between animals that received yogurt (82%) and those that received placebo (75%). Yogurt did not induce any significant changes in intestinal flora, whether it was produced with Lactobacillus acidophilus or Lactobacillus GG. In conclusion, in acute prehepatic portal hypertension, bacteriotherapy with Lactobacillus was unable to induce changes in bacterial translocation probably because it was unable to induce changes in bacterial flora.

Entities:  

Mesh:

Year:  2003        PMID: 12822876     DOI: 10.1023/a:1023729115659

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  48 in total

1.  Survival of Lactobacillus species (strain GG) in human gastrointestinal tract.

Authors:  B R Goldin; S L Gorbach; M Saxelin; S Barakat; L Gualtieri; S Salminen
Journal:  Dig Dis Sci       Date:  1992-01       Impact factor: 3.199

2.  Effect of Lactobacillus supplementation with and without arginine on liver damage and bacterial translocation in an acute liver injury model in the rat.

Authors:  D Adawi; F B Kasravi; G Molin; B Jeppsson
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

Review 3.  Lactulose, lactic acid bacteria, intestinal microecology and mucosal protection.

Authors:  S Salminen; E Salminen
Journal:  Scand J Gastroenterol Suppl       Date:  1997

4.  Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites.

Authors:  C Guarner; B A Runyon; S Young; M Heck; M Y Sheikh
Journal:  J Hepatol       Date:  1997-06       Impact factor: 25.083

5.  Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria.

Authors:  M F Bernet; D Brassart; J R Neeser; A L Servin
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

6.  Relationship between cecal population levels of indigenous bacteria and translocation to the mesenteric lymph nodes.

Authors:  E K Steffen; R D Berg
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

7.  Effect of perorally administered lactobacilli on macrophage activation in mice.

Authors:  G Perdigon; M E de Macias; S Alvarez; G Oliver; A A de Ruiz Holgado
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

8.  A prospective study of bacterial infections in patients with cirrhosis.

Authors:  W R Caly; E Strauss
Journal:  J Hepatol       Date:  1993-07       Impact factor: 25.083

9.  Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis.

Authors:  J M Llovet; R Bartolí; R Planas; E Cabré; M Jimenez; A Urban; I Ojanguren; J Arnal; M A Gassull
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

10.  Small bowel bacterial overgrowth in patients with alcoholic cirrhosis.

Authors:  F C Morencos; G de las Heras Castaño; L Martín Ramos; M J López Arias; F Ledesma; F Pons Romero
Journal:  Dig Dis Sci       Date:  1995-06       Impact factor: 3.199

View more
  9 in total

Review 1.  Gut microbiota-related complications in cirrhosis.

Authors:  Isabel Gómez-Hurtado; José Such; Yolanda Sanz; Rubén Francés
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 2.  Probiotics in management of hepatic encephalopathy.

Authors:  Barjesh Chander Sharma; Jatinderpal Singh
Journal:  Metab Brain Dis       Date:  2016-04-28       Impact factor: 3.584

3.  Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.

Authors:  Juan P Arab; Rosa M Martin-Mateos; Vijay H Shah
Journal:  Hepatol Int       Date:  2017-05-26       Impact factor: 6.047

4.  Diagnosis and management of bacterial infections in decompensated cirrhosis.

Authors:  Maria Pleguezuelo; Jose Manuel Benitez; Juan Jurado; Jose Luis Montero; Manuel De la Mata
Journal:  World J Hepatol       Date:  2013-01-27

5.  Oral administration of Saccharomyces boulardii ameliorates carbon tetrachloride-induced liver fibrosis in rats via reducing intestinal permeability and modulating gut microbial composition.

Authors:  Ming Li; Lin Zhu; Ao Xie; Jieli Yuan
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

6.  Prevention and management of bacterial infections in cirrhosis.

Authors:  Sunil K Taneja; Radha K Dhiman
Journal:  Int J Hepatol       Date:  2011-08-28

7.  Microbiome dysbiosis and alcoholic liver disease.

Authors:  Fengyuan Li; Craig J McClain; Wenke Feng
Journal:  Liver Res       Date:  2019-09-06

8.  Microbial translocation in chronic liver diseases.

Authors:  Marilia Rita Pinzone; Benedetto Maurizio Celesia; Michele Di Rosa; Bruno Cacopardo; Giuseppe Nunnari
Journal:  Int J Microbiol       Date:  2012-07-17

Review 9.  Probiotics and Alcoholic Liver Disease: Treatment and Potential Mechanisms.

Authors:  Fengyuan Li; Kangmin Duan; Cuiling Wang; Craig McClain; Wenke Feng
Journal:  Gastroenterol Res Pract       Date:  2015-12-29       Impact factor: 2.260

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.